HLB Pharmaceutical Co. Ltd Total Liabilities
HLB Pharmaceutical Co. Ltd total liabilities. Based on the latest financial reports, HLB Pharmaceutical Co. Ltd (047920) has total liabilities worth ₩46.98 Billion KRW (≈ $31.84 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check HLB Pharmaceutical Co. Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of HLB Pharmaceutical Co. Ltd (2014–2024)
Total liabilities of HLB Pharmaceutical Co. Ltd from 2014 to 2024. This chart illustrates how HLB Pharmaceutical Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore HLB Pharmaceutical Co. Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.
HLB Pharmaceutical Co. Ltd Competitors by Total Liabilities
The table below lists competitors of HLB Pharmaceutical Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Easy Trip Planners Limited
NSE:EASEMYTRIP
|
India | Rs4.04 Billion |
|
FG Imperii Acquisition Corp. Class A Ordinary Shares
NASDAQ:FGII
|
USA | $1.20K |
|
Hua Jung Components Co Ltd
TWO:5328
|
Taiwan | NT$461.18 Million |
|
Shanghai Jin Jiang International Hotels Development Co Ltd B
SHG:900934
|
China | $30.00 Billion |
|
UTKARSH SMALL FINANCE BANK ORD (BSE)
NSE:UTKARSHBNK
|
India | Rs256.73 Billion |
|
Genesyslogic
TWO:6104
|
Taiwan | NT$1.74 Billion |
|
Batavia Prosperindo Int
JK:BPII
|
Indonesia | Rp3.40 Trillion |
|
Lewis Group Limited
JSE:LEW
|
South Africa | ZAC3.67 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down HLB Pharmaceutical Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is HLB Pharmaceutical Co. Ltd's balance sheet.
Liquidity & Leverage Metrics
HLB Pharmaceutical Co. Ltd Total Liabilities Ratios Explained
HLB Pharmaceutical Co. Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HLB Pharmaceutical Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HLB Pharmaceutical Co. Ltd (2014–2024)
The table below shows the annual total liabilities of HLB Pharmaceutical Co. Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩41.53 Billion ≈ $28.15 Million |
-21.93% |
| 2023-12-31 | ₩53.20 Billion ≈ $36.05 Million |
-5.42% |
| 2022-12-31 | ₩56.25 Billion ≈ $38.12 Million |
+14.22% |
| 2021-12-31 | ₩49.25 Billion ≈ $33.37 Million |
-26.27% |
| 2020-12-31 | ₩66.80 Billion ≈ $45.27 Million |
+130.06% |
| 2019-12-31 | ₩29.04 Billion ≈ $19.68 Million |
+49.48% |
| 2018-12-31 | ₩19.42 Billion ≈ $13.16 Million |
-15.71% |
| 2017-12-31 | ₩23.04 Billion ≈ $15.62 Million |
+3.16% |
| 2016-12-31 | ₩22.34 Billion ≈ $15.14 Million |
+76.31% |
| 2015-12-31 | ₩12.67 Billion ≈ $8.59 Million |
-23.77% |
| 2014-12-31 | ₩16.62 Billion ≈ $11.26 Million |
-- |
About HLB Pharmaceutical Co. Ltd
HLB Pharmaceutical Co., Ltd. researches and develops peptide drugs in South Korea. The company offers skeletal muscle relaxant, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, anti… Read more